approval
saveSKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
community read0 votes
Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 205d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 205d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 217d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 217d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 401d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 401d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 520d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 520d ago
same company · ±60 days · 5
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 16, 2022
- approvalvenetoclax: VENCLEXTA (VENETOCLAX) — FDA approvalJun 15, 2022
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 11, 2022
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 11, 2022
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalApr 29, 2022
comments(0)
5-min edit window · permanent after that